The effect of cyclophosphamide on leukocyte kinetics and susceptibility to infection in patients with Wegener's granulomatosis.
D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D001853:Bone Marrow / Q000187:drug effects*; D001854:Bone Marrow Cells; D002675:Child, Preschool; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D014890:Granulomatosis with Polyangiitis / Q000150:complications / Q000188:drug therapy*; D006410:Hematopoiesis / Q000187:drug effects*; D006801:Humans; D007165:Immunosuppression Therapy; D007239:Infections / Q000209:etiology*; D007275:Injections, Intravenous; D007958:Leukocyte Count; D007962:Leukocytes / Q000187:drug effects*; D007970:Leukopenia / Q000139:chemically induced; D008214:Lymphocytes / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D009000:Monocytes / Q000187:drug effects; D009504:Neutrophils / Q000187:drug effects; D010761:Phosphorus Radioisotopes; D012852:Sinusitis / Q000209:etiology; D014397:Tuberculosis, Pulmonary / Q000209:etiology
D010761:Phosphorus Radioisotopes; D003520:Cyclophosphamide